Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetonitrile SCHEMBL1526829 | 1.00 | TDP1 (0.61) | TDP1TSHR | |
| Acetonitrile SCHEMBL28125497 | 0.96 | TDP1 (0.57) | TDP1TSHR | |
| Acetonitrile SCHEMBL4429686 | 0.93 | TDP1 (0.53) | TDP1TSHR | |
| Water SCHEMBL4030267 | 0.83 | — | — | |
| Cyanate SCHEMBL28209292 | 0.81 | TDP1 (0.57) | TDP1TSHR | |
| SCHEMBL28239025 | 0.81 | TDP1 (0.57) | TDP1TSHR | |
| Water SCHEMBL28300228 | 0.79 | TDP1 (0.80) | TDP1 | |
| SCHEMBL27928984 | 0.78 | TDP1 (1.00) | TDP1TSHR | |
| SCHEMBL2020 | 0.78 | — | — | |
| SCHEMBL1332279 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5025098-A | — | — | None | — | — | JP | disclosed |
| US-12269841-B2 | Production method for oligonucleotides | AJINOMOTO CO., INC. (JP) | 2025-04-08 | — | — | US | disclosed |
| US-20240173345-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDE AND NUCLEOSIDE FOR TREATING VIRAL INFECTIONS | EMORY UNIVERSITY | 2024-05-30 | — | — | US | disclosed |
| EP-4333859-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO | Emory University (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3043803-B1 | NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND THEIR USES | UNIV EMORY (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11312688-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-26 | — | — | US | disclosed |
| EP-3925964-A1 | PRODUCTION METHOD FOR OLIGONUCLEOTIDES | AJINOMOTO CO., INC. (JP) | 2021-12-22 | — | — | EP | disclosed |
| US-20210371450-A1 | PRODUCTION METHOD FOR OLIGONUCLEOTIDES | AJINOMOTO CO., INC. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | EMORY UNIVERSITY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20140031406-A1 | PYRAZOLE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8569353-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-20130116296-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2013-05-09 | — | — | US | disclosed |
| EP-2391619-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| CN-1245375-C | Process for synthesizing N,N-diisopropyl ethylenediamine | UNIV ZHEJIANG (CN) | 2006-03-15 | — | — | CN | disclosed |
| CN-1634856-A | Process for synthesizing N,N-diisopropyl ethylenediamine | UNIV ZHEJIANG (CN) | 2005-07-06 | — | — | CN | disclosed |
| JP-H0525098-A | PRODUCTION OF N,N-DI-SUBSTITUTED ETHYLENEDIAMINE | KOEI CHEM CO LTD | 1993-02-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166973-B2 | Substituted nucleotides and nucleosides for treating viral infections | PNP, TYMP, HPRT1 | TDP1 341/4885TSHR 2261/4885 |
| US-11857560-B2 | Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections | SLC28A1, PNP, SLC28A2 | TDP1 978/4885TSHR 3619/4885 |
| US-11312688-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | TDP1 4230/4885TSHR 123/4885 |
| US-20130116296-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | TDP1 4230/4885TSHR 123/4885 |
| US-20240173345-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SUBSTITUTED NUCLEOTIDE AND NUCLEOSIDE FOR TREATING VIRAL INFECTIONS | PNP, NTPCR, TYMP | TDP1 259/4885TSHR 3703/4885 |
| US-20110003807-A1 | Thiazole derivatives | MTOR, RICTOR, AKT2 | TDP1 2609/4885TSHR 1608/4885 |
| US-20210371450-A1 | PRODUCTION METHOD FOR OLIGONUCLEOTIDES | RNGTT, DCLRE1B, PHOSPHO1 | TDP1 320/4885TSHR 3297/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | TDP1 2138/4885TSHR 2433/4885 |
| US-20140031406-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | TDP1 4230/4885TSHR 123/4885 |
| US-12269841-B2 | Production method for oligonucleotides | RNGTT, DCLRE1B, PHOSPHO1 | TDP1 320/4885TSHR 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.